Preoperative and postoperative systemic therapy for operable non–small-cell lung cancer
Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …
Hyperprogressive disease: recognizing a novel pattern to improve patient management
S Champiat, R Ferrara, C Massard, B Besse… - Nature reviews Clinical …, 2018 - nature.com
Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …
survival of a subset of patients across multiple solid tumour types, but other patients can …
Vorasidenib in IDH1-or IDH2-mutant low-grade glioma
IK Mellinghoff, MJ Van Den Bent… - … England Journal of …, 2023 - Mass Medical Soc
Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …
[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE …
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis
Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …
Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III …
M Boyer, MAN Şendur, D Rodríguez-Abreu… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement
Background In patients undergoing aortic-valve or mitral-valve replacement, either a
mechanical or biologic prosthesis is used. Biologic prostheses have been increasingly …
mechanical or biologic prosthesis is used. Biologic prostheses have been increasingly …
Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in …
PURPOSE The purpose of this study was to evaluate the prognostic value of Immunoscore
in patients with stage III colon cancer (CC) and to analyze its association with the effect of …
in patients with stage III colon cancer (CC) and to analyze its association with the effect of …
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed …
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed …